A new ADA consensus report (May 28, 2025, Diabetes Care) provides a clinical framework for screening, diagnosing, and managing metabolic dysfunction–associated steatotic liver disease (MASLD) in people with type 2 diabetes (T2D), prediabetes, and type 1 diabetes with obesity.